

## An In-depth Overview of the Worldwide Efforts to Develop the COVID-19 Vaccine and Their Efficacies

Dr. MSc Jeyatheepan Jeyaretnam

DOI: <https://doi.org/10.52845/mcrr/2025/08-05-6>

**Abstract:** The rapid development and deployment of vaccines against COVID-19 represent a landmark achievement in modern medicine and global collaboration. This article provides a comprehensive overview of the global efforts to develop COVID-19 vaccines, highlighting various technological platforms, the role of adjuvants and delivery systems, and a comparative analysis of vaccine efficacies. In addition, a bibliometric analysis of scientific publications offers insight into research trends and future directions. This review aims to synthesize current knowledge and perspectives to inform ongoing and future vaccine strategies.

### INTRODUCTION

The emergence of SARS-CoV-2 in late 2019 triggered a global health crisis, causing widespread morbidity and mortality. Vaccination became the cornerstone of the international response, aiming to reduce disease severity, transmission, and fatalities. Historically, vaccine development spans several years; however, unprecedented scientific collaboration and funding accelerated the development of COVID-19 vaccines within months (Krammer, 2020). This review outlines the landscape of

COVID-19 vaccine development, analyzes different technological approaches, and evaluates their effectiveness and broader implications.

### CURRENT COVID-19 VACCINE LANDSCAPE

Several COVID-19 vaccines have received emergency use authorization or full approval worldwide. The table below summarizes key vaccines, their platforms, and reported efficacy:

| Vaccine                         | Platform          | Reported Efficacy | Notes                                         |
|---------------------------------|-------------------|-------------------|-----------------------------------------------|
| Pfizer-BioNTech (BNT162b2)      | mRNA              | >90%              | High efficacy; requires ultra-cold storage    |
| Moderna (mRNA-1273)             | mRNA              | >90%              | Similar to Pfizer-BioNTech                    |
| Oxford-AstraZeneca (ChAdOx1-S)  | Viral Vector      | 60–80%            | Efficacy varies by dosing and demographics    |
| Johnson & Johnson (Ad26.COV2.S) | Viral Vector      | ~66%              | Single-dose vaccine                           |
| Sinovac (CoronaVac)             | Inactivated Virus | Moderate          | Widely used in Asia and South America         |
| Sinopharm (BBIBP-CorV)          | Inactivated Virus | Moderate          | Similar to Sinovac                            |
| Novavax (NVX-CoV2373)           | Protein Subunit   | High              | Demonstrated high efficacy in clinical trials |

Global vaccination efforts have led to the administration of billions of doses, but disparities persist in low- and middle-income countries due to logistical and economic constraints (World Health Organization [WHO], 2024).

### VACCINE PLATFORMS

COVID-19 vaccines were developed using various platforms, each with distinct advantages and challenges:

- **mRNA Vaccines:** Utilize messenger RNA to instruct cells to produce the spike protein, eliciting an immune response. Benefits include rapid development and strong immunogenicity (Pardi et al., 2018).
- **Viral Vector Vaccines:** Use a harmless virus to deliver genetic material. These are stable and easy to store but may have reduced efficacy in populations with preexisting immunity to the vector.
- **Inactivated Vaccines:** Contain killed virus particles, providing a broad immune response but often requiring adjuvants and multiple doses.

- **Protein Subunit Vaccines:** Consist of purified pieces of the virus, typically requiring adjuvants to enhance the immune response.
- **DNA Vaccines:** Still largely experimental in humans but offer stability and ease of production.

### ADJUVANTS, MRNA SEQUENCE MODIFICATIONS, FORMULATIONS, AND DELIVERY SYSTEMS

Adjuvants such as aluminum salts and novel molecules like Matrix-M are used to boost immune responses in traditional and protein-based vaccines. mRNA vaccines are optimized via codon optimization and incorporation of pseudouridine to enhance stability and reduce immunogenicity of the RNA itself (Pardi et al., 2018). Lipid nanoparticles (LNPs) protect mRNA and facilitate cellular delivery. Cold-chain requirements remain a challenge, particularly for mRNA vaccines requiring ultra-low storage temperatures. Innovations in delivery, such as needle-free injectors and nasal sprays, are under investigation.

## COVID-19 VACCINE-RELATED PUBLICATION TREND ANALYSIS

The pandemic has spurred an explosion of scientific publications. Between 2020 and 2024, thousands of papers were published across domains including vaccine development, clinical trials, immunology, and public health. The U.S., China, and European nations lead in publication volume. Journals such as *Nature*, *The Lancet*, and *NEJM* featured high-impact studies. Trends also show a shift from early vaccine efficacy studies to long-term immunity, booster strategies, and variant-specific responses. The proliferation of preprints also underscores the urgency and dynamic nature of COVID-19 research.

## PERSPECTIVES

COVID-19 vaccine development has set a precedent for rapid biomedical innovation. However, challenges remain:

- **Variants:** New strains like Delta and Omicron exhibit partial resistance to existing vaccines, necessitating updates and boosters.
- **Booster Shots:** Emerging evidence supports booster doses to maintain immunity, especially in vulnerable populations.
- **Equity:** Global access remains uneven, with initiatives like COVAX striving to bridge the gap.
- **Future Directions:** Universal coronavirus vaccines, mucosal immunization strategies, and integration of AI in vaccine design represent promising avenues.

## Acknowledgments:

We acknowledge the contributions of researchers, healthcare

workers, and organizations worldwide who played critical roles in the development and dissemination of COVID-19 vaccines.

## Author Contributions:

Writing – Original Draft: Dr. Med Jeyatheepan Jeyaretnam  
SP-MSc

## REFERENCES

- [1]. Krammer, F. (2020). SARS-CoV-2 vaccines in development. *Nature*, 586(7830), 516–527. <https://doi.org/10.1038/s41586-020-2798-3>
- [2]. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. *Nature Reviews Drug Discovery*, 17(4), 261–279. <https://doi.org/10.1038/nrd.2017.243>
- [3]. Polack, F. P., Thomas, S. J., Kitchin, N., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *The New England Journal of Medicine*, 383(27), 2603–2615. <https://doi.org/10.1056/NEJMoa2034577>
- [4]. Voysey, M., Clemens, S. A. C., Madhi, S. A., et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222). *The Lancet*, 397(10269), 99–111. [https://doi.org/10.1016/S0140-6736\(20\)32661-1](https://doi.org/10.1016/S0140-6736(20)32661-1)
- [5]. Sadoff, J., Gray, G., Vandebosch, A., et al. (2021). Safety and efficacy of single-dose Ad26.COV2.S vaccine. *The New England Journal of Medicine*, 384(23), 2187–2201. <https://doi.org/10.1056/NEJMoa2101544>
- [6]. World Health Organization. (2024). WHO COVID-19 dashboard. Retrieved from <https://covid19.who.int/>